Acute myeloid leukemia (AML) starts in the bone marrow, which is the soft inner parts of bones. With acute types of leukemia, such as AML, bone marrow cells do not mature. These immature cells, often called blast cells, keep building up. Without treatment, AML can quickly become life-threatening. Because it is an acute type of leukemia, it can spread quickly to the blood and to other parts of the body, such as lymph nodes, liver, spleen, brain, spinal cord, and testicles. • According to 2018 report by World Cancer Research Fund, there were a total of 437,033 leukemia cases recorded, worldwide, in 2018. Out of these, more than 160,000 are estimated to be from the Asia-pacific region. AML is one of the major types of leukemia in the Asia-pacific region, comprising of approximately 28% of leukemia patients in Asia-pacific. Hence, the estimated prevalence of AML in Asia-pacific is 1.4 per 100,000.

The Asia Pacific PACS and RIS market is estimated to grow at a CAGR of 8.1% from 2019 - 2027. The market of PACS and RIS in the Asia Pacific region is majorly contributed by the Japan. Factors leading to the growth of the PACS and RIS Market in Asia Pacific are, rising incidence as well as mortality rates of cancer, awareness about early diagnosis. The market of PACS and RIS is expected to reach up to US$ 1,223.18 Mn by the end of 2027. The top 10 industry players operating in the market of PACS and RIS across the globe includes McKesson Corporation, General Electric, Fujifilm Holdings Corporation, Koninklijke Philips N.V., Siemens AG, Cerner Corporation, IBM, Novarad, Agfa-Gevaert Group, and INFINITT Healthcare Co., Ltd.

The Asia Pacific mobile cardiac telemetry systems market is estimated to grow at a CAGR of 12.1% from 2019 - 2027. The Asia Pacific mobile cardiac telemetry systems market includes the consolidated markets for China, Japan, India, Australia, South Korea and Rest of Asia Pacific. Asia Pacific region occupies a third position in the global mobile cardiac telemetry systems market and is expected to register robust growth rate during the forecast period. The region is the fastest growing market for the mobile cardiac telemetry systems in the global scenarios. The top 10 industry players operating in the market of mobile cardiac telemetry systems across the globe includes Medtronic, BioTelemetry Inc., Applied Cardiac Systems, Inc, Medicomp Inc, Preventice Services, LLC, The Scottcare Corporation, Medi-Lynx (Subisidiary Of Medicalgorithmics, S.A), Zoll Medical Corporation, Welch Allyn, and Telerhythmics, LLC.

Medical tourism is one of the driving factors that is leading to the growth of medical equipment maintenance in the Asia Pacific region. With increasing costs of manufacturing against their practices, the medical device manufacturers are struggling to generate enough revenue to please their investors. The developing economies in the region are expected to be the crucial factor in offering better and profitable growth opportunities for the major players to expand their business and geographic reach. The patients travel to the countries due to the use of sophisticated and advanced medical technology products, devices, and equipment. Medical tourism takes place in cases where surgeries and medical care are required.

Apheresis is a medical technique, where the blood of an individual, either a donor or patient, is passed through an apparatus that separates a particular constituent and returns the rest of the blood to the circulatory system. This is an extracorporeal therapy. The market size provided in the report has been derived from the revenue generated by products. For estimating the market size of the product, the average selling price (ASP) of a product in the region has been multiplied with the sales volume (new sales and replacement rate, based on applicability).

2019 年10 月09 日，国家卫生健康委、国家中医药管理局联合发布《关于提升社会办医疗机构管理能力和医疗质量安全水平的通知》（以下简称《通知》），《通知》指出各级卫生健康行政部门和各质控中心要将社会办医疗机构纳入统一的医疗质量管理体系，实施与公立医疗机构同等标准的管理。

2019 年1-9 月，医药行业主要运行指标呈现以下特点：一是行业固定资产投资保持增长，投资额同比增长7.0%；二是医药行业工业增加值累计增速为6.9%；三是行业零售额继续保持较高增速，累计增速为10.1%；四是医药行业营业收入和利润保持增长，营业务收入和利润总额同比增长分别为8.4%和10.0%。

2019 年1-8 月，医药行业主要运行指标呈现以下特点：一是行业固定资产投资保持增长，投资额同比增长7.4%；二是医药行业工业增加值累计增速为6.9%；三是行业零售额继续保持较高增速，累计增速为10.6%；四是医药行业营业收入和利润保持增长，营业务收入和利润总额同比增长分别为8.5%和9.5%。

为贯彻落实医保支付方式改革任务，切实做好疾病诊断相关分组(DRG)付费国家试点工作，2019 年10 月24 日，国家医保局正式公布了《国家医疗保障DRG 分组与付费技术规范》和《国家医疗保障DRG（CHS-DRG）分组方案》，要求各试点城市按照此次发布的统一技术规范和分组方案开展有关工作，使CHS-DRG 成为国家医保领域的“通用语言”，以利于DRGs 推广应用。未来，随着DRGs 的落地将会有利于规范医疗行为、促进医疗信息化业务、推进分级诊疗、助推商业医保推广等。